Labcyte News Logo

Labcyte Announces Collaboration with Notable Labs

Sunnyvale, CA, and San Francisco, CA. 7 December 2016.  Labcyte Inc. and Notable Labs today announced a collaboration to apply the unique capabilities of Labcyte’s revolutionary Echo® acoustic liquid handling technology to screen individual cancer patients’ tumor cells.  This functional screening identifies which available drugs or drug combinations may be most effective at treating their cancer.

“Our service is designed to provide information that may help clinicians prioritize the best available options for individualized patient care in an actionable timeframe,” said Pete Quinzio, co-founder of Notable Labs.  “Our belief is that testing drugs directly on patients’ cancer cells will lead to a better understanding of biological mechanisms of disease, improve treatment success, and reduce unnecessary side effects.”

Labcyte’s acoustic liquid handling technology uses sound energy to transfer samples and reagents more precisely, accurately and cost-effectively than traditional methods, enabling entirely new capabilities that are difficult or impossible to accomplish with other techniques.  Acoustic liquid handling technology is contactless, eliminating the use of pipettes and reducing the volumes required for compounds and samples.

Notable Labs will utilize the unique attributes of Labcyte’s Echo liquid handler in a fully automated, high-throughput laboratory to functionally assess the effects of FDA-approved drugs on live primary cancer cells from individual patients.  The various chemotherapies, targeted agents, and non-oncology classes of drugs can be tested alone and in combinations to identify efficacy and specificity against cancer, in a way that was not possible before.

Mark Fischer-Colbrie, Chief Executive Officer of Labcyte commented “Augmenting today’s precision medicine efforts with functional screening could dramatically improve outcomes for patients and reduce healthcare costs by utilizing a more comprehensive data set to identify potential drug or drug combinations for an individual patient.  With such promise for saving lives, we are committed to doing everything we can to accelerate the development of this strategy and expand its use.  We applaud Notable Labs, a pioneer in this field in North America, for their vision and their efforts to improve and enhance patient care.”

About Labcyte Inc.

Labcyte, a global biotechnology tools company headquartered in Sunnyvale, California, is revolutionizing liquid handling. Echo® liquid handling systems use sound to precisely transfer liquids without contact, eliminating the use of pipettes.  Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions.  Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 58 U.S. patents and others internationally.  For more information, visit

About Notable Labs

Notable Labs’ mission is to change the way cancer is treated, which starts with putting patients first.  The company is developing a personalized treatment service for cancer patients that will prioritize combinations of FDA-approved treatments that can be immediately prescribed by a doctor.  Focusing on individual patients and existing treatments, the company is discovering novel uses of drugs and defining mechanisms underlying development of cancer progression and drug resistance.  Using modern data science and robotics, Notable Labs is building a scalable, iterative model with the ultimate aim of turning treatment selection into a data problem.  Headquartered in San Francisco, California, the company is currently partnering with clinicians at several research hospitals in the United States and Canada to identify promising, actionable treatments for relapsed and refractory acute leukemia patients.  For more information, visit

For Further Information, please contact Vicky La Touche-Price, Seroba Life Sciences on +3531 6334028.

Recent Articles

Endotronix News

FDA Approval for Endotronix Pivotal Trial

Dublin, Ireland and LISLE, IL, USA – AUGUST 1, 2019 – Seroba’s portfolio company, Endotronix, Inc., a digital health and […]

Read More
Quanta News

Quanta Raises $48 million in Series C Funding Round

Alcester, Warwickshire, UK, 29 July 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical […]

Read More
Endotronix News

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial

LISLE, IL – JULY 15, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the […]

Read More
Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top